Tempus AI

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Tempus AI

Jul 29, 2024, 09:27 | Career

Ezequiel Renzulli: I am excited to announce the launch of Rio Sur Advisory Partners

Ezequiel Renzulli, Chief Executive Officer at Rio Sur Advisory Partners, shared on LinkedIn: "After six…

Jul 21, 2024, 12:32 | Blog

CancerX Moonshot's updated Solutions Catalog

CancerX Moonshot shared a post on LinkedIn: "We’ve updated our Solutions Catalog! . The…

Jun 8, 2024, 11:24 | Blog

Kristiyana Kaneva: Packed several days at ASCO with Tempus AI

Kristiyana Kaneva, Executive Medical Director, Clinical Development at Tempus AI, shared a post on LinkedIn:…

May 1, 2024, 06:04 | Insight

Martin Stumpe: Predicting MSI in prostate cancer from hematoxylin and eosin stained biopsy

Martin Stumpe, Chief of AI at Tempus, shared on LinkedIn: “We recently published a paper…

Dec 13, 2023, 17:53 | Blog

Earle Burgess: Why don’t all advanced prostate cancer patients with pathogenic HRR gene mutations respond to parp inhibitors?

Earle Burgess, Chief of Genitourinary Oncology Section at Atrium Health, Levine Cancer Institute, shared a…

All: 5 Posts: 1 - 100